Welcome to our dedicated page for Aptose Bioscienc news (Ticker: APTO), a resource for investors and traders seeking the latest updates and insights on Aptose Bioscienc stock.
Aptose Biosciences Inc (APTO) is a clinical-stage biotechnology company pioneering precision therapies for hematologic malignancies. This page serves as the definitive source for verified news and scientific updates related to APTO's innovative oncology pipeline.
Key resources include: Press releases on clinical trial progress, regulatory milestones, partnership announcements with pharmaceutical collaborators, and analyses of treatment mechanisms. Investors will find essential updates on the company's small molecule inhibitors and combination therapy developments targeting AML and high-risk MDS.
Our news collection enables: Tracking of APTO's progress in genetic-guided therapies, monitoring of FDA interactions, and insights into strategic collaborations advancing personalized cancer treatments. Content is curated to meet investor and researcher needs without promotional bias.
Bookmark this page for real-time updates on APTO's scientific advancements and corporate developments. Always consult official filings for investment decisions.
Aptose Biosciences (TSX:APS) announced that KPMG LLP, its current independent registered public accounting firm, will not stand for re-appointment for the Company's 2025 annual audit, effective April 15, 2025. KPMG will continue reviewing quarterly interim financial results through Q2 2025.
KPMG made this decision without seeking Aptose's consent, and neither the Board of Directors nor the Audit Committee participated in this decision. KPMG previously issued unqualified reports for fiscal years 2024 and 2023.
Notably, KPMG communicated concerns regarding a material weakness in internal control over financial reporting, specifically related to accounting for complex financial instruments (warrants) as disclosed in the Company's 2024 Form 10-K. Aptose has initiated the process to appoint a new independent registered public accounting firm.
Aptose Biosciences (TSX: APS), a clinical-stage precision oncology company, has announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto, scheduled for May 5-6, 2025. The company, which is developing a tuspetinib (TUS) based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML) patients, will be represented by Dr. William G. Rice, Chairman, President and CEO.
Dr. Rice will deliver a corporate presentation on May 5, 2025, at 3:00 p.m. EDT. The presentation will be available via webcast and will also be accessible on the Aptose website. Additionally, the management team will be conducting one-on-one meetings during the conference, which interested parties can schedule through their conference representatives.
Aptose Biosciences (NASDAQ: APTO, TSX:APS), a clinical-stage precision oncology company, announced that its common shares will be delisted from the Nasdaq Stock Market effective April 2, 2025. The delisting follows the company's failure to comply with Nasdaq's Listing Rule 5550(b)(1) equity requirement by the March 31, 2025 deadline, as mandated by the Nasdaq Hearings Panel's December 17, 2024 decision.
The company, which develops tuspetinib-based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML), will continue trading on the Toronto Stock Exchange (TSX) under the symbol 'APS'. Aptose's management and board will review available options, including appealing the determination, while maintaining focus on executing their business plan and seeking future listing on a U.S. national Securities Exchange.
Aptose Biosciences (NASDAQ: APTO, TSX: APS) reported its 2024 year-end results and corporate updates, highlighting progress in its tuspetinib (TUS)-based triple drug therapy for acute myeloid leukemia (AML). The TUSCANY Phase 1/2 trial, combining TUS with venetoclax and azacitidine, has shown promising results with complete remissions in TP53-mutated and FLT3-wildtype AML patients.
The company secured approximately $37 million in financing during 2024, including a $10 million loan from Hanmi Pharmaceutical. In March 2025, Hanmi converted $1.5 million of debt into 409,063 common shares. Aptose also entered a CRADA with the National Cancer Institute for clinical development collaboration.
Financial results show a net loss of $25.4 million for 2024, down from $51.2 million in 2023. Research and development expenses decreased to $15.1 million from $36.8 million. The company's cash position of $6.7 million is expected to fund operations until April 2025.
Aptose Biosciences (NASDAQ: APTO), a clinical-stage precision oncology company, has regained compliance with Nasdaq's minimum bid price requirement. The company received confirmation from Nasdaq that its common shares maintained a closing bid price of $1.00 or higher for ten consecutive business days through March 14, 2025.
While this resolves the minimum bid price compliance issue, Aptose remains non-compliant with Nasdaq's $2.5 million shareholders' equity requirement. The company is currently operating under a Hearing Panel exception that provides additional time to meet this requirement, though compliance is not guaranteed.
Aptose is developing tuspetinib (TUS)-based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML) patients.
Aptose Biosciences (NASDAQ: APTO, TSX: APS) announced positive results from its Phase 1/2 TUSCANY trial, testing tuspetinib (TUS) in combination with venetoclax and azacitidine for newly diagnosed AML patients. The Clinical Safety Review Committee approved dose escalation from 40mg to 80mg TUS following favorable results from the first cohort.
Key findings from the initial 40mg cohort of four patients include: complete responses in difficult-to-treat TP53-mutated/CK AML and FLT3-wildtype AML patients, no dose-limiting toxicities, no prolonged myelosuppression, and no required dose reductions to standard-of-care components. Three FLT3-WT patients completed Cycle 1 with two achieving complete remissions. The fourth patient with FLT3-ITD and NPM1 mutations is still in Cycle 1.
The trial aims to enroll 18-24 patients by mid-late 2025, with multiple U.S. sites participating. Pharmacokinetic analyses showed TUS plasma levels were unaffected by AZA addition, and venetoclax levels remained consistent with previous studies.
Aptose Biosciences (NASDAQ: APTO, TSX: APS) announced a 1-for-30 reverse share split approved by its board of directors. The consolidation will reduce outstanding common shares from 64,301,183 to approximately 2,143,372 shares. This strategic move aims to restore compliance with Nasdaq's minimum bid price requirement and maintain broad investor accessibility.
The reverse split is pending TSX approval, with trading of post-split shares expected to begin on February 26, 2025. No fractional shares will be issued, and registered shareholders will receive instructions via a Letter of Transmittal to exchange their certificates. The consolidation will proportionally adjust all outstanding warrants, convertible notes, stock options, and other convertible securities.
Aptose Biosciences (NASDAQ: APTO, TSX: APS) has announced two significant financial arrangements: a $25 million Committed Equity Facility with an institutional investor and a new At-The-Market (ATM) facility. The Committed Equity Facility gives Aptose the option, over 24 months, to sell up to $25 million of common shares to the investor, subject to regulatory conditions. Additionally, the company has established an ATM facility to sell shares on Nasdaq with an aggregate offering price of up to $1 million.
The company has filed Prospectus Supplements with the SEC for both offerings. No shares will be sold on the TSX or other Canadian trading markets under the common share purchase agreement. The TSX has conditionally approved the committed equity facility based on Section 602.1 of the TSX Company Manual.
Aptose Biosciences (NASDAQ: APTO, TSX: APS) reported promising early results from its Phase 1/2 TUSCANY trial testing tuspetinib in combination with venetoclax and azacitidine (TUS+VEN+AZA triplet) for newly diagnosed acute myeloid leukemia (AML) patients.
Key findings from the first cohort of four patients receiving the lowest dose (40mg) include:
- Two FLT3-wildtype patients achieved complete remissions by end of Cycle 1
- One patient with biallelic TP53 mutations achieved complete remission
- One patient showed significant reduction in bone marrow leukemic blasts
- The fourth patient with FLT3-ITD and NPM1 mutations is still in Cycle 1
The treatment showed favorable safety with no dose-limiting toxicities or dose adjustments needed. The TUSCANY trial aims to enroll 18-24 patients by mid-late 2025, testing various doses of tuspetinib with standard dosing of venetoclax and azacitidine.
Aptose Biosciences (NASDAQ: APTO, TSX: APS) has initiated dosing of the first patients in its TUSCANY Phase 1/2 study, testing tuspetinib (TUS) in combination with venetoclax (VEN) and azacitidine (AZA) as a frontline triple therapy for newly diagnosed acute myeloid leukemia (AML) patients.
The TUS+VEN+AZA triplet therapy aims to provide an improved frontline treatment option that is effective across diverse AML populations. Earlier APTIVATE trials showed that TUS, both as a single agent and combined with VEN, demonstrated favorable safety and broad activity in relapsed or refractory AML patients, including those with prior-VEN and prior-FLT3 inhibitor therapies.
The TUSCANY study will evaluate various doses and schedules of TUS with standard dosing of azacitidine and venetoclax in AML patients ineligible for induction chemotherapy. Starting at 40mg once daily, the trial plans to enroll 18-24 patients by mid-late 2025 across multiple U.S. sites.
